Laurus Labs Limited
LAURUSLABS.NS
Get informed when a big investor buys or sells
+ FollowMarket Cap$1.1T
Close$
Share Statistics
| Market cap | $1.10 Trillion |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $2.00 (0.10%) |
| Earnings per Share | $16.47 |
| Beta | 0.43 |
| Outstanding Shares | 539,794,420 |
Return
| Return on Equity | NaN% |
|---|---|
| Return on Assets | NaN% |
| Return on Invested Capital | NaN% |
Valuation & Multiples
| P/E Ratio | 100.57 |
|---|---|
| PEG | 80.14 |
| Price to Sales | 15.2 |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 24, 2026
EPS Estimate
$4.91
Average shareholder expectationRevenue Estimate
$18.35 B
Average shareholder expectationNext Earnings Call
Expected Date
October 22, 2026
EPS Estimate
$6.68
Average shareholder expectationRevenue Estimate
$20.82 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Laurus Labs Limited
7,059 employees
CEO: Satyanarayana Chava Operating both domestically in India and internationally, Laurus Labs Limited, through its various subsidiaries, is a diversified pharmaceutical company engaged in the research, development, manufacturing, and commercialization of both a...